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Breast Milk from Tanzanian Women Has Divergent
Effects on Cell-Free and Cell-Associated HIV-1 Infection
In Vitro
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Abstract
Transmission of HIV-1 during breastfeeding is a significant source of new pediatric infections in sub-Saharan Africa. Breast
milk from HIV-positive mothers contains both cell-free and cell-associated virus; however, the impact of breast milk on HIV-1
infectivity remains poorly understood. In the present study, breast milk was collected from HIV-positive and HIV-negative
Tanzanian women attending antenatal clinics in Dar es Salaam. Milk was analyzed for activity in vitro against both cell-free
and cell-associated HIV-1. Potent inhibition of cell-free R5 and X4 HIV-1 occurred in the presence of milk from all donors
regardless of HIV-1 serostatus. Inhibition of cell-free HIV-1 infection positively correlated with milk levels of sialyl-LewisX
from HIV-positive donors. In contrast, milk from 8 of 16 subjects enhanced infection with cell-associated HIV-1 regardless of
donor serostatus. Milk from two of these subjects contained high levels of multiple pro-inflammatory cytokines including
TNFa, IL-1b, IL-6, IL-8, MIP-1a, MIP-1b, MCP-1 and IP-10, and enhanced cell-associated HIV-1 infection at dilutions as high as
1:500. These findings indicate that breast milk contains innate factors with divergent activity against cell-free and cellassociated HIV-1 in vitro. Enhancement of cell-associated HIV-1 infection by breast milk may be associated with
inflammatory conditions in the mother and may contribute to infant infection during breastfeeding.
Citation: Lyimo MA, Mosi MN, Housman ML, Zain-Ul-Abideen M, Lee FV, et al. (2012) Breast Milk from Tanzanian Women Has Divergent Effects on Cell-Free and
Cell-Associated HIV-1 Infection In Vitro. PLoS ONE 7(8): e43815. doi:10.1371/journal.pone.0043815
Editor: Derya Unutmaz, New York University, United States of America
Received June 7, 2012; Accepted July 26, 2012; Published August 28, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This study was supported by the National Institutes of Health (NIH) AIDS International Training and Research Program/Fogarty International Center at
The Geisel School of Medicine at Dartmouth, Howard Hughes Medical Institute Undergraduate Research Award, and a Veterans Affairs Merit Review Award. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Ruth.I.Connor@Dartmouth.edu
¤a Current address: Department of Hematology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
¤b Current address: Department of Health Sciences, Karolinska Institute, Stockholm, Sweden

constitute another form of innate immunity against infection with
pathogens, including HIV-1 [11–13].
In the milieu of breast milk, less is known about the impact of
milk factors on cell-associated HIV-1. In contrast to cell-free HIV1 infection, cell-associated infection arises from direct cell-to-cell
transfer of virus to susceptible target cells. Cell-to-cell spread of
HIV-1 in culture is significantly more efficient than spread of cellfree virus and involves formation of a transient yet complex
virological synapse [14–17], which is more difficult to neutralize
[15].
Administration of highly active antiretroviral therapy (HAART)
to HIV-positive women for the prevention of mother-to-child
transmission (PMTCT) during breastfeeding is associated with a
rapid decrease in the levels of cell-free HIV-1 RNA in breast milk
[18] and a dramatic reduction in HIV transmission [19–23].
Transmission rates of less than 2% have been reported in clinical
studies of HAART for PMTCT [19–21], confirming the
effectiveness of this intervention. The reason for residual
transmission of HIV-1 in this setting is not clear; however, recent

Introduction
Transmission of HIV-1 from mother to child during breastfeeding results from the presence of both cell-free virus and HIVinfected cells in the milk [1,2]. The mechanisms associated with
HIV-1 breast milk transmission not well understood; however, the
low incidence of infection among most breastfeeding infants of
HIV-1 seropositive mothers suggests that HIV-1 transmission is
relatively inefficient and supports a protective role for breast milk
in preventing viral infection [3]. In clinical studies, components in
breast milk, including IL-15 [4], long-chain fatty acids [5] and
erythropoietin [6] have been linked to lower rates of post-natal
HIV-1 transmission. In vitro, breast milk mucin (MUC1) effectively
blocks binding and transfer of virus from dendritic cells (DC) to
CD4+ T cells [7,8] and inhibits HIV-1 infection [9,10]. The
inhibitory effects of MUC1 are attributed to a rich array of
repeating LewisX motifs, consistent with a direct role for LewisX in
preventing binding of HIV-1 to DC-SIGN [7,8]. Human milk
oligosaccharides and glycans, which are abundant in breast milk,
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studies have documented transient periods of viremia among
women receiving HAART for PMTCT based on intermittent
detection of HIV-1 RNA in maternal plasma and breast milk [24].
The presence of a cell-associated reservoir for HIV-1 in breast
milk is also suggested by two independent clinical studies
documenting the persistence of proviral DNA in breast milk from
women receiving HAART during breastfeeding [18,25]. Taken
together, these findings suggest distinct mechanisms that determine the persistence and infectivity of cell-free and cell-associated
HIV-1 in breast milk.
In the present study, we sought to evaluate the impact of breast
milk on infection of CD4+ target cells by cell-free and cellassociated HIV-1 in vitro. Our findings suggest that breast milk may
have divergent activities against cell-free HIV-1 as compared to
cell-associated virus, and this may have implications for understanding the pathogenesis of HIV-1 transmission during breastfeeding and in the setting of HAART for PMTCT.

HIV-1 Isolates
HIV-1 isolates used for this study included strains with tropism
for CCR5 (R5, HIV-1BaL) and CXCR4 (X4, HIV-1HC4). Virus
stocks were propagated in phytohemagglutinin (PHA)-activated
peripheral blood mononuclear cells (PBMC) and titered on TZMbl cells (NIH AIDS Research and Reference Reagent Program,
contributed by Dr. John C. Kappes, Dr. Xiaoyun Wu and
Tranzyme, Inc.).

Cell-free HIV-1 Infectivity Assays
The effect of breast milk on cell-free HIV-1 infection was
determined by measuring viral Tat-driven activation of the HIV-1
LTR and luciferase expression in TZM-bl cells as previously
described [26]. In brief, TZM-bl cells were plated in 96-well plates
at a density of 16104 cells/well in 100 ml of Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 1% fetal bovine serum
(FBS), antibiotics and amphotericin B. Cell-free HIV-1 (100
TCID50) was incubated with five-fold serial dilutions of milk for
15 min prior to addition to TZM-bl cells. Each milk sample was
tested in triplicate wells of the plate. The cells were exposed to the
mixture of milk and HIV-1 for 24 hrs at 37uC. Following this
incubation, the cells were washed and assessed for viability using a
methane thiosulfonate (MTS)-based solution (CellTiter 96H
Aqueous One Solution Cell Proliferation Assay, Promega, WI)
according to the manufacturer’s instructions. The cells were then
lysed and luciferase activity was measured in cell lysates using the
Bright-GloTM Luciferase Assay System (Promega, WI). Luciferase
activity was quantified in Relative Light Units (RLU) using a
LMaxII384 luminometer (Molecular Devices, Sunnyvale, CA).
Baseline activation of luciferase expression with media or milk
alone (in the absence of added HIV-1) was also determined.
Percent (%) inhibition or enhancement of HIV-1 infection was
calculated by the following formula: 1-([RLU milk + HIV] –
[RLU milk alone])/([RLU media +HIV] – [RLU media alone]) 6
100%.

Materials and Methods
Ethics Statement
Protocols for this study were approved by the Institutional
Review Boards from the Muhimbili University of Health and
Allied Sciences (MUHAS, Dar es Salaam, Tanzania) and Dartmouth College (Hanover, NH). Written informed consent was
obtained from all donors prior to collection of milk samples.

Breast Milk Donors
Breast milk was obtained from 20 women (10 HIV-positive and
10 HIV-negative) enrolled in the antenatal clinic of Muhimbili
National Hospital (MNH) in Dar es Salaam, Tanzania, where
routine counseling and testing for HIV infection is performed. The
HIV-positive milk donors were enrolled in the PMTCT clinic,
which is affiliated with the regular antenatal clinic at MNH.
Information about methods for preventing mother-to-child transmission of HIV-1 and infant feeding options were made available
to HIV-positive milk donors through PMTCT counseling sessions
conducted by a nurse at the clinic.
To be eligible for the study, women had to have healthy infants
who were breastfeeding without difficulty. Breastfeeding mothers
with reported signs and symptoms of mastitis were excluded. A
medication history was obtained and included information about
administration of single-dose Nevirapine (sdNVP) during delivery
and/or ARV treatment received at any time prior to donating
breast milk.

Cell-associated HIV-1 Infectivity Assays
To assess the effects of breast milk on cell-associated HIV-1
infection, HIV-infected peripheral blood CD4+ T lymphocytes
were co-cultured with TZM-bl cells in the presence or absence of
milk as described [26]. The levels of luciferase activity were then
quantified as an indicator of HIV-1 infection of the TZM-bl target
cells. In brief, primary CD4+ T lymphocytes were first enriched
from PBMC and activated for 48 hr with PHA. Cells were then
washed and resuspended in fresh media containing 100 U/mL of
interleukin-2 (IL-2), followed by infection with HIV-1BAL for 5
days at 37uC prior to use. One day before the experiment, TZMbl cells were seeded into the wells of a 96-well plate (16104 cells/
well) and allowed to adhere overnight. On the day of the
experiment, serial dilutions of milk were added to designated wells
of TZM-bl cells, followed by the addition of washed, HIV-infected
CD4+ T lymphocytes at a final density of 16105 lymphocytes per
well. After 24 hrs, the cells were lysed directly in the wells with
Beta-Glo reagent (Promega, Madison WI) and luciferase activity
was quantified. Controls included TZM-bl cells co-cultured with
uninfected CD4+ T lymphocytes in the presence of either media or
milk. Additionally, to control for any cell-free HIV-1 released from
the infected lymphocytes during co-culture, an equivalent number
of HIV-infected CD4+ lymphocytes was seeded into wells in the
absence of TZM-bl target cells. The supernatant from these wells,
containing cell-free virus, was collected after 24 hrs and added to
TZM-bl cells. The effect of breast milk on TZM-bl infection by
this cell-free virus was also evaluated.

Breast Milk Samples
Milk was collected from either the left or the right breast by
manual self-expression. Samples were collected $1 hr after the
infant last breastfed from the designated side. Milk was collected
into sterile plastic tubes and immediately stored and transported at
4uC. Initial processing was performed in the laboratory at MNH
within 4 hrs of collection. Whole breast milk was centrifuged at
10,0006g for 10 min to separate the cell pellet from the fluid phase
of the milk. The cell pellet was washed three times using sterile
PBS and stored at 280uC. The lipid layer of the milk was removed
manually and the skim milk fraction was aliquoted into 1 mL
cryovials and stored at 280uC. The skim milk and cell pellets were
shipped on dry ice to The Geisel School of Medicine at
Dartmouth for further analyses. Before use in experiments, each
aliquot of skim milk was again centrifuged at 10,0006g for 5 min
to remove any residual lipid and sterile-filtered through a 0.22
micron Millex-GVH filter (Millipore, Billerica, MA). Individual
milk samples were not pooled for any experiments.
PLOS ONE | www.plosone.org
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Multiplex and ELISA Cytokine Assays

Statistical Analysis

The levels of cytokines, chemokines and growth factors in breast
milk samples were measured using commercially available
multiplex assays (Bio-Rad Laboratories, Hercules, CA) in
conjunction with the DartLab Immune Monitoring Core Facility
at The Geisel School of Medicine at Dartmouth. Results were
quantified based on individual standard curves generated for each
cytokine and the data analyzed using Bio-Plex ManagerTM
software. SDF-1a was measured in breast milk using a commercially available ELISA (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions.

GraphPad Prism v.4 (GraphPad Software, Inc, La Jolla, CA)
was used to calculate t-tests and Mann-Whitney U tests. A oneway and two-way analysis of variance (ANOVA) was used to
perform group comparisons. Student t-test was used to compare
means 6 standard error of the mean. Mann-Whitney U test was
used to compare the median percent inhibition of HIV-1 and
concentration of cytokines present in the milk from the HIVpositive and HIV-negative donors. Spearman’s correlations were
used to correlate the concentrations of specific cytokines and the
inhibitory activity against cell-free HIV-1. A p-value of #0.05 was
used to indicate significance.

LewisX ELISA

Results

Measurement of LewisX in breast milk was carried out by
standard ELISA. Milk samples were diluted 1:10 in
0.2 M NaHCO3 buffer, pH 9.6. The diluted samples (100 ml/
well) were added to ELISA plates (Maxisorp plates, Nunc) and
incubated overnight at 4uC. The plates were washed three times
with Tris-buffered saline (TBS)/0.05% Tween 20 [TBST]) buffer
and blocked with TBS/1% BSA for 30 min at room temperature.
After washing with TBST, the plates were incubated with either
mouse anti-human LewisX IgM or mouse anti-human sialylLewisX IgM monoclonal antibodies (Calbiochem, San Diego, CA)
for 2 hr at room temperature, followed by washing with TBST
and detection with goat anti-mouse IgM-horseradish peroxidase
conjugate (Thermo Scientific/Pierce Biotechnology, Rockford,
IL). After washing to remove unbound antibodies, the plates were
developed using the 1-StepTM Turbo TMB-ELISA reagent
(Thermo Scientific/Pierce Biotechnology) at room temperature.
The reaction was stopped after 30 min by the addition of 1 M
H2SO4 and the plates were read on an ELISA plate reader at
A450 nm.

Characteristics of Tanzanian Breast Milk Donors
Breast milk was obtained from a total of 20 HIV-positive and
HIV-negative mothers enrolled in the antenatal clinic at MNH.
The HIV-positive women were in regular attendance at the
PMTCT clinic, where they received counseling on strategies for
preventing HIV-1 transmission to their infants. Although the HIVpositive women were enrolled in the PMTCT clinic, none
reported having taken either sdNVP or any combination of
ARV therapy. They acknowledged being offered medication at
delivery, but declined to take it.
Women with clinical mastitis were excluded from the study
based on physical evaluation and specific questions about the
presence of pain, swelling and discharge from the breasts. The
characteristics of the milk donors are summarized (Table 1). All
milk samples were obtained from women within 42 days postpartum. Among these, colostrum samples were collected within
three days post-partum from two HIV-positive and two HIVnegative donors. The average time of breast milk collection postpartum from HIV-positive donors (12.4 days) was less than that of
HIV-negative donors (19.3 days); however, this difference was not
statistically significant. This difference was likely due to close
follow-up of HIV-positive women enrolled in the PMTCT clinic
as compared to healthy HIV-negative women who had no medical
indication for more frequent follow-up.

Quantitative Real-time PCR Assay
Real-time PCR was used to quantify HIV-1 proviral DNA in
cell pellets from individual breast milk samples. Total cellular
genomic DNA was isolated from milk cell pellets using a Qiagen
blood minikit (Qiagen, Valencia CA). DNA samples were then
assayed by real-time PCR for HIV-1 proviral DNA using primers
and molecular beacons with broad specificity for different HIV-1
genotypes [27]. Conserved sequences within the HIV-1 gag gene
were amplified with primers gagF (59-ATAATCCACCTATCCCAGTAGGAGAAAT-39 and gagR (59-TTTGGTCCTTGT
CTTATG TCCAGAATG-39) and detected using the molecular
beacon HIV-1/FAM, 59GCGAGCCTGGGATTAAATAAAATAGTAAGAATGTATAGCGCTCGC-39 with the quencher
DABCYL. Proviral DNA copy number was quantified based on
a standard curve generated from 10-fold serial dilution (from 108
to 101 copies) of an HIV-1 plasmid of known copy number. The
number of cell equivalents was quantified by amplification of
CCR5 sequences using the primers CCR5-590 (59-CTTCATCATCCTCCTGACAATCG-39) and CCR5rc890 (59- GATTC
CCGAGTAGCAGATGACC-39) and the molecular beacon
CCR5/FAM, CGAAGCTTGGGTGGTGGCTGTGTTTGCT
TCG with the quencher DABCYL. All PCR reactions were
carried out in duplicate in a final volume of 50 ml using HotStartIT Probe qPCR master mix for real-time PCR (USB Corporation,
Cleveland OH). Cycling conditions for both CCR5 and HIV
quantification were denaturation (95uC, 5 min) followed by 45
cycles of amplification (95uC, 15 sec; 50uC, 30 sec; 72uC, 30 sec)
using an Applied Biosystems 7300 Real-Time PCR System.

PLOS ONE | www.plosone.org

Breast Milk from HIV-positive and HIV-negative Donors
Inhibits Cell-free R5 HIV-1
To determine if breast milk from HIV-positive women affects
cell-free HIV-1 infection in vitro, TZM-bl cells were infected with
R5 HIV-1BaL in the presence of five-fold serial dilutions (from 1:4
to 1:2500) of milk. The effect of mature milk from HIV-positive
(n = 8) and HIV-negative (n = 8) donors was evaluated. Significant
inhibition of cell-free HIV-1BaL was observed using milk from both
HIV-positive donors (dotted line) and HIV-negative donors (solid
line) beginning at a 1:4 dilution (Figure 1). At this dilution, the
median percent inhibition of HIV-1 was 85% (range 68%–90.5%)
for HIV-positive donors and 64% (range 61%–75.5%) for HIVnegative donors. Although there was a trend toward greater
inhibitory activity associated with milk from HIV-positive donors
as compared to HIV-negative donors, this difference did not reach
statistical significance. The inhibitory activity of breast milk from
all donors decreased in direct relation to further dilution of the
milk. Only minimal inhibitory activity was observed at a 1:2500
dilution using milk from either HIV-positive or HIV-negative
donors.
Together, these results demonstrate potent HIV-1 inhibitory
activity against cell-free R5 HIV-1 in mature milk from both HIVpositive and HIV-negative subjects. Similar results were obtained
against cell-free HIV-1BaL using colostrum samples obtained from
3
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Table 1. Characteristics of Tanzanian breast milk donors.

HIV-positive (n = 10)

HIV-negative (n = 10)

Average age of mother (yrs)

27.5 (range 16–40)

26.5 (range 21–37)

PMTCT medication taken

No

N/A

ARV medication taken

No

N/A

Symptomatic breast illness

No

No

Average time of milk collection (days post-partum)

12.4 (range 1–28)

19.3 (range 2–42)

doi:10.1371/journal.pone.0043815.t001

two HIV-positive and two HIV-negative donors. Compared to
mature milk, colostrum had more potent inhibitory activity at a
1:500 dilution (50% versus 24%). However, the inhibitory activity
of colostrum was significantly decreased at a 1:2500 dilution, a
finding that was similar to that observed for mature milk.
Additional experiments were performed to compare the
inhibitory activity of breast milk against HIV-1 isolates with
difference tropism. Individual milk samples were evaluated against
R5-tropic (HIV-1BaL) and X4-tropic (HIV-1HC4) strains of HIV-1.
Among HIV-positive donors, HIV-inhibitory activity in breast
milk ranged from 45–96% against HIV-1BaL, and from 25–94%
against HIV-1HC4. Overall, milk from each donor was able to
inhibit both strains of cell-free HIV-1, and there was a significant
correlation between the ability to inhibit R5 and X4 strains
(R2 = 0.596, p = 0.025).
Similar findings were observed using breast milk from HIVnegative donors, demonstrating a significant correlation between
the HIV-inhibitory activity against cell-free R5 and X4 HIV-1
(R2 = 0.599, p = 0.024). Again, there was a trend toward higher
inhibitory activity among milk samples from the HIV-positive
donors as compared to HIV-negative donors, similar to our earlier
observation (Fig. 1); however, this difference was not statistically
significant.
For three HIV-positive donors, sequential breast milk samples
were obtained 2 weeks apart. When assayed for HIV-inhibitory
activity, milk from 2 of the 3 donors maintained a consistent level
of inhibition against cell-free R5 HIV-1BAL between the first and
second time points, while the inhibitory activity of milk from the
third donor declined (data not shown).

Levels of Breast Milk MIP-1a, MIP-1b, RANTES and SDF-1a
do not Correlate with Cell-free HIV-inhibitory Activity
We next explored whether the HIV-inhibitory activity of breast
milk against cell-free HIV-1 was associated with increased
concentrations of the ligands for the HIV-1 co-receptors, CCR5
and CXCR4. Levels of MIP-1a, MIP-1b, RANTES and SDF-1a
were quantified in the milk of HIV-positive and HIV-negative
subjects. The concentration of milk MIP-1a was very low in the
majority of samples tested, with mean concentrations of 42.1 pg/
ml and 80.1 pg/ml for HIV-positive and HIV-negative donors,
respectively. There was no significant difference in the mean level
of MIP-1b, (998.3 vs 842.1 pg/ml, Mann-Whitney, p = 0.21) or
RANTES (173.2 vs 146.1 pg/ml, Mann-Whitney, p = 0.66), when
comparing milk samples from HIV-positive versus HIV-negative
donors. The mean concentration of SDF-1a was significantly
higher in the milk of HIV-positive donors as compared to HIVnegative donors (1,525 vs 1,189 pg/ml; Mann-Whitney,
p = 0.009).
To determine if the levels of breast milk MIP-1a, MIP-1b,
RANTES or SDF-1a correlate with inhibitory activity against cellfree HIV-1 in vitro, concentrations of each factor were compared to
the percent HIV-inhibition for the same sample. Spearman’s
correlations were performed for MIP-1a, MIP-1b, RANTES and
SDF-1a and the inhibitory activity of all milk samples from both
HIV-positive and HIV-negative donors. The results of these
comparisons revealed no significant correlation between the level
of MIP-1a, MIP-1b, RANTES or SDF-1a in milk and cell-free
HIV-inhibitory activity for all donors, independent of HIV-1
serostatus. Additionally, there was no correlation between the
concentration of MIP-1a, MIP-1b, RANTES or SDF-1a in milk
and the percent inhibitory activity against cell-free HIV-1 when
comparing HIV-positive and HIV-negative donors in separate
analyses.

Breast Milk Contains Elevated Levels of Inflammatory
Cytokines
Breast milk from both HIV-positive and HIV-negative donors
was further evaluated for the presence of an expanded range of
cytokines, chemokines and growth factors using a multiplex panel.
Among milk samples from all donors, considerable variation was
observed in the range of concentrations of the factors measured
(Figure 2). In particular, IL-6, IL-8, MIP-1a, MIP-1b, MCP-1 and
IP-10 had $1 log variation among donors. Of note, subject 002+
(HIV-positive) and subject 002- (HIV-negative) were remarkable
for having significantly higher concentrations of multiple inflammatory factors, including TNFa, IL-1b, IL-6, IL-8, MIP-1a, MIP1b, MCP-1 and IP-10 in their milk as compared to other donors.
No significant differences were observed in the levels of individual
immune factors among milk samples from HIV-positive and HIVnegative donors, and no significant correlations were found

Figure 1. Inhibition of cell-free HIV-1 by breast milk. Mature
breast milk from HIV-positive (n = 8) and HIV-negative (n = 8) donors
was evaluated for inhibition of cell-free HIV-1 in TZM-bl cell assays. Cells
were infected with R5 HIV-1BaL in the presence of five-fold serial
dilutions of breast milk. Percent inhibition was calculated relative to
control cultures infected with HIV-1BaL in the absence of added breast
milk. HIV-inhibitory activity of breast milk from HIV-positive (dotted line)
and HIV-negative (solid line) donors is shown (mean 6 SD).
doi:10.1371/journal.pone.0043815.g001
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Figure 2. Immune factors in breast milk from Tanzanian donors. The concentrations of multiple immune factors including cytokines,
chemokines and growth factors were measured in breast milk samples using a multiplex panel. Data for each factor is expressed as concentration
(pg/mL) and is presented for all donors irrespective of HIV serostatus.
doi:10.1371/journal.pone.0043815.g002

LewisX or sialyl-LewisX among HIV-negative donors or the levels
of LewisX among HIV-positive donors (Fig. 3A–C). However, a
significant correlation was observed among HIV-positive donors
between the levels of sialyl-LewisX in milk and cell-free HIVinhibitory activity (R2 = 0.657) (Fig. 3D). These results support a
possible role for sialyl-LewisX in breast milk in preventing cell-free
HIV-1 infection of susceptible CD4+ target cells.

between the level of individual cytokines in milk and inhibition of
cell-free HIV-1.

Sialyl-LewisX in Breast Milk from HIV-positive Donors
Correlates with Inhibition of Cell-free HIV-1
Previous studies have indicated a role for the blood group
antigen LewisX in blocking the interaction between HIV-1gp120
and DC-SIGN expressed on dendritic cells (DC) [8]. Similarly,
epithelial-derived MUC1 in breast milk, which contains multiple
repeating LewisX motifs, has been implicated in preventing cellfree HIV-1 transmission to DC and infection of CD4+ T cells [8–
10]. In the present study, levels of LewisX and sialyl-LewisX were
measured in the breast milk of Tanzanian donors. Results
demonstrate the presence of both LewisX and sialyl-LewisX in
the milk of all donors, with distinct clustering of low and high
expression patterns among individual donors (Figure 3). When
compared with HIV-inhibitory activity against cell-free R5- or X4tropic virus, no correlation was found between the levels of milk
PLOS ONE | www.plosone.org

Breast Milk Enhances Cell-associated HIV-1 Infection in
vitro
In further experiments, we assessed the ability of breast milk to
inhibit cell-associated HIV-1 infection in vitro. The effect of milk
at dilutions of 1:4, 1:20, 1:100 and 1:500 was evaluated in TZM-bl
cells co-cultured with HIV-infected primary CD4+ T lymphocytes.
In contrast to our results using cell-free virus, inhibition of cellassociated HIV-1 was observed with milk from only 2 of 16
donors, and then only at the lowest dilution (1:4) (Figure 4).
Moreover, significant enhancement of cell-associated HIV-1
5
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Figure 3. LewisX and sialyl-LewisX in breast milk. Levels of LewisX and sialyl-LewisX were measured by ELISA in breast milk samples from both
HIV-positive and HIV-negative donors. The results were then compared to cell-free HIV-inhibitory activity for the same samples. Data is expressed as
the percent inhibition of cell-free R5 (%) and X4 (¤) HIV-1 relative to the levels of either LewisX or sialyl-LewisX measured for each sample.
doi:10.1371/journal.pone.0043815.g003

HIV-positive as compared to HIV-negative subjects, suggesting
both innate and adaptive immune factors may contribute to the
overall anti-viral effect of the milk.
Previously, we found that breast milk from HIV-negative
donors in the United States potently inhibited cell-free HIV-1
infection in vitro, suggesting the presence of innate anti-viral factors
at relatively high abundance in breast milk [26]. Here, we confirm
the inhibitory effect of breast milk on cell-free HIV-1 using
samples obtained from both HIV-positive and HIV-negative
women from sub-Saharan Africa. The anti-viral activity against
cell-free HIV-1 did not correlate with the presence or levels of
individual cytokines, chemokines or growth factors in the milk,
including factors that serve as blocking ligands for the HIV-1 coreceptors, CCR5 and CXCR4.
However, a correlation was found between HIV-inhibitory
activity and the siaylated form of the blood group antigen LewisX
in the milk of HIV-positive women. LewisX and MUC1 isolated
from breast milk have been shown to inhibit binding of cell-free
HIV-1 to DC-SIGN and to prevent transfer of infection to CD4+
T cells [8–10]. The observed correlation between breast milk
inhibitory activity against cell-free HIV-1 and levels of sialylLewisX in milk suggests sialic acid residues may play a key role in
blocking cell-free viral infection. The presence of sialic acid motifs
at the ends of carbohydrate side chains has been shown to
significantly reduce the inherent infectivity of both SIV and HIV-1
[28,29], while digestion with neuraminindase, which cleaves sialyl
moieties, enhances viral infectivity and increases cell-cell syncytium formation in vitro [28].
Despite the finding of potent inhibitory activity against cell-free
HIV-1, breast milk from the same subjects had no inhibitory effect

infection was observed in the presence of milk from both HIVpositive and HIV-negative donors. Even at dilutions as high as
1:500, milk from two donors, Subject 002+ (HIV-positive) and
Subject 002- (HIV-negative), significantly enhanced cell-associated
HIV-1 infection (Fig. 4). As noted earlier, milk from these donors
had significantly higher levels of multiple inflammatory factors. No
correlation was found between the levels of LewisX or sialylLewisX in milk samples and the observed enhancing activity
against cell-associated HIV-1 (data not shown), suggesting that
distinct factors influence the impact of breast milk on cell-free
versus cell-associated virus.

Detection of Proviral DNA in Breast Milk Cells
To determine whether enhancement of cell-associated HIV
infection by breast milk in vitro was associated with the presence of
HIV-infected cells in vivo, we used quantitative real-time PCR to
assess proviral load in breast milk cells isolated from the HIV-1
positive donors in this study. HIV-1 proviral DNA was detected by
real-time PCR in 4 of 9 donors tested. Of those donors with
detectable proviral DNA in their breast milk cells, 3 of 4 were
found to have breast milk that significantly enhanced cellassociated HIV-1 infection in vitro.

Discussion
The results of this study demonstrate significant inhibition of
cell-free HIV-1 by breast milk from both HIV-positive and HIVnegative Tanzanian women. Inhibition of cell-free virus was
largely independent of viral tropism; however, there was a trend
toward higher levels of inhibition of cell-free HIV-1 with milk from
PLOS ONE | www.plosone.org
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Figure 4. Enhancement of cell-associated HIV-1 infection by breast milk. Breast milk from HIV-positive and HIV-negative donors was
evaluated for activity against cell-associated HIV-1 infection in TZM-bl cell assays. Breast milk was tested at 5-fold serial dilutions (1:4, 1:20, 1:100 and
1:500). Percent inhibition or enhancement of cell-associated R5 HIV-1BAL is shown for breast milk samples from individual HIV-positive (open circles)
and HIV-negative (closed circles) donors.
doi:10.1371/journal.pone.0043815.g004

lial cells [31,32], suggesting other molecules are critical to the
formation of a tight adhesive junction in this setting.
Alternatively, activation of HIV-1 expression from latently
infected cells, and/or enhanced release of virions into the synaptic
cleft, may be promoted by the presence of stimulatory factors in
breast milk. Cell-associated HIV-1 in breast milk is found
primarily in infected CD4+ T lymphocytes and macrophages
[33–35]. When stimulated in vitro, HIV-infected milk cells secrete
higher levels of virus than the comparable population of cells from
peripheral blood [35]. Recently, activated milk CD4+ T cells from
women receiving HAART were shown to produce HIV-1 in vitro,
suggesting that these cells may constitute a reservoir that is
relatively refractive to treatment [36].
Activation of HIV-1 transcription is known to be modulated by
immune cytokines [37], and it is possible that high levels of
inflammatory factors in breast milk may play a role in enhancing
HIV-1 release from infected cells. Among the subjects in this
study, markedly elevated concentrations of multiple inflammatory
factors were observed in milk from two subjects, and milk from
these subjects also enhanced infection with cell-associated HIV-1
at dilutions up to 1:500 (the highest dilution tested).
Inflammatory conditions in the breast, including mastitis, are
known to increase the risk of HIV-1 transmission during

on cell-associated HIV infection in vitro. Rather, a significant
proportion of milk from individual donors, including both HIVpositive and HIV-negative subjects, enhanced the level of cellassociated HIV-1 infection. Enhancement did not correlate with
levels of sialyl-LewisX in the milk or with the presence of individual
cytokines or chemokines, indicating that distinct factors in breast
milk modulate cell-free versus cell-associated HIV-1 infection.
Enhancement of cell-cell interaction and HIV-1 infection in the
presence of breast milk may result from up-regulation of cell
surface molecules needed for efficient attachment and interaction
of HIV-infected milk cells to target cells in the intestinal epithelium
or submucosal tissue. Formation of a virological synapse between
HIV-infected and uninfected cells is characterized by a tight
adhesive junction, involving HIV-1 gp120 binding to CD4, and
membrane interaction with adhesion molecules, including ICAM1 [30]. Breast milk contains high levels of soluble ICAM-1
(sICAM-1), which might inhibit cell-cell adhesion and modulate
cell-associated HIV-1 infection. We measured the levels of
sICAM-1 in the milk of subjects in this study, and found a range
of concentrations (Fig. 2A), but no correlation with inhibition or
enhancement of cell-associated HIV-1 infection. Earlier studies
reported no effect of blocking antibodies against ICAM-1 in
preventing adhesion of HIV-infected lymphocytic cells to epithe-
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breastfeeding [38–40]. Mothers in this study were screened at
enrollment, and those with clinical signs and symptoms of mastitis
were excluded. However, subclinical mastitis may also increase the
levels of inflammatory factors in breast milk. Studies by Kantarci,
et al. [41] found a positive correlation between subclinical mastitis,
increased milk Na/K ratios, and higher numbers of HIV-infected
cells in milk from HIV-infected Tanzanian mothers who
transmitted HIV-1 to their infants through breastfeeding. While
anecdotal, our results demonstrate that in vitro exposure of HIVinfected cells to breast milk containing high levels of multiple
inflammatory factors can significantly enhance cell-associated
HIV-1 infection.
Further studies are needed to determine the mechanisms of
enhancement of cell-associated HIV-1 infection by breast milk.
Localized and systemic inflammatory responses in the mother may
contribute by increasing the levels of proinflammatory factors in
the milk. Among HIV-infected mothers, this may represent an
increased risk of virus transmission during breastfeeding. Moreover, the failure of breast milk to block cell-associated HIV-1 may
be associated with maintenance of a cellular reservoir of virus in
breast milk and may contribute to the residual transmission of

HIV-1 to breastfeeding infants among women receiving HAART
during lactation.
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